Kyntra Bio Posts $0.04 Q3 EPS, Kills FG-3246, Ties Phase 3 to New Financing
KYNB is trading near its 52-week low of $3.02 (6.0% above the low) on elevated volume (2.1× avg).
Summary
Kyntra Bio reported $1.8 million of Q3 revenue and $0.2 million of income from continuing operations, discontinued its FG-3246 prostate cancer program, and said the roxadustat Phase 3 will start in 1Q 2027 only if it signs a partner or raises capital.
Key Events · Earnings and Guidance · KYNB
-
FG-3246 Program Discontinued
A pre-specified Phase 2 interim analysis in mCRPC showed efficacy below the required threshold, so Kyntra closed enrollment and scrapped FG-3246 and FG-3180.
-
Phase 3 Contingent on Financing
The pivotal Phase 3 roxadustat trial in LR-MDS with high transfusion burden is planned for 1Q 2027, but only subject to a strategic partnership or an external capital raise.
-
Q3 Results and Cash Runway
Revenue was $1.8 million versus $1.1 million a year ago and income from continuing operations was $0.2 million ($0.04 per share); cash, equivalents, investments and receivables totaled $44.1 million at September 30, 2026, funding operations into 2028.
-
Cost Savings From Termination
Ending the FG-3246 study is expected to save over $20 million in operating expenses across 2027 and 2028.
Analysis · KYNB · Life Sciences
The pipeline reset is the headline: FG-3246 and FG-3180 are dead after the Phase 2 interim look missed its efficacy bar, cutting more than $20 million of spending in 2027-2028 but leaving roxadustat as the whole story. That story is not yet funded — management says the pivotal Phase 3 in LR-MDS will only start in 1Q 2027 if it lands a strategic partnership or raises outside capital. With $44.1 million of cash and equivalents plus receivables and a runway into 2028, there is time, but the stock is already under a Nasdaq delisting determination from October 6, so a dilutive raise or a partner deal is the next thing that reprices it. The quarter itself was small but clean: $1.8 million of revenue and $0.2 million of income from continuing operations versus a $13.1 million loss a year ago, helped by a $14.0 million gain on debt restructuring.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYNB was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $3.02 to $10.47. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.